Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales

References

• Bonomo RA, Burd EM, Conly J, et al. Carbapenemase-producing organisms: a global scourge. Clin Infect Dis. 2018;66(8):1290–1297. doi:10.1093/cid/cix893
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36. doi:10.1093/infdis/jiw282
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang WL, Zhang W, et al. Risk factors and outcomes of carbapenem-resistant Enterobacteriaceae infection after liver transplantation: a retrospective study in a Chinese Population. Infect Drug Resist. 2020;13:4039–4045. doi:10.2147/IDR.S278084
   PubMed Web of Science ®Google Scholar
• Ferstl PG, Filmann N, Brandt C, et al. The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease. Liver Int. 2017;37(10):1488–1496. doi:10.1111/liv.13438
   PubMed Web of Science ®Google Scholar
• Pagani N, Corcione S, Lupia T, et al. Carbapenemase-producing Klebsiella pneumoniae colonization and infection in solid organ transplant recipients: a single-center, retrospective study. Microorganisms. 2021;9(11):2272. doi:10.3390/microorganisms9112272
   PubMed Web of Science ®Google Scholar
• Sun Y, Zheng H, Zhang JL, et al. [Clinical characteristics of carbapenem-resistant Enterobacteriaceae infection in pediatric liver transplantation recipients]. Zhonghua Er Ke Za Zhi. 2020;58(8):640–645. Chinese. doi:10.3760/cma.j.cn112140-20200316-00239
   Google Scholar
• Sun Y, Yu L, Gao W, et al. Investigation and analysis of the colonization and prevalence of carbapenem-resistant Enterobacteriaceae in pediatric liver transplant recipients. Infect Drug Resist. 2021;14:1957–1966. doi:10.2147/IDR.S304998
   Web of Science ®Google Scholar
• Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, et al. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. J Antimicrob Chemother. 2021;76(1):220–225.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Tanaka M, Yamamoto M, et al. High prevalence of carbapenem resistance among plasmid-mediated AmpC β-lactamase-producing Klebsiella pneumoniae during outbreaks in liver transplantation units. Int J Antimicrob Agents. 2015;45(1):33–40. doi:10.1016/j.ijantimicag.2014.08.015
   Web of Science ®Google Scholar
• Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565–S575. doi:10.1093/cid/ciz830
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatric Infect Dis Soc. 2020;9(1):56–66. doi:10.1093/jpids/piz085
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01964-16
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00883-17
   Web of Science ®Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.021
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Bradley JS, Roilides E, Broadhurst H, et al. Safety and efficacy of ceftazidime-avibactam in the treatment of children ≥3 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38(9):920–928. doi:10.1097/INF.0000000000002395
   Web of Science ®Google Scholar
• Bradley JS, Broadhurst H, Cheng K, et al. Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children ≥3 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial. Pediatr Infect Dis J. 2019;38(8):816–824. doi:10.1097/INF.0000000000002392
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters; 2019. Available from: http://www.eucast.org. Accessed September 15, 2021.
   Google Scholar
• Shen L, Lian C, Zhu B, et al. Bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae: a single-center retrospective study on risk factors and therapy options. Microb Drug Resist. 2021;27(2):227–233. doi:10.1089/mdr.2019.0455
   Web of Science ®Google Scholar
• CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• Hopkins KL, Meunier D, Naas T, Volland H, Woodford N. Evaluation of the NG-Test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases. J Antimicrob Chemother. 2018;73(12):3523–3526. doi:10.1093/jac/dky342
   PubMed Web of Science ®Google Scholar
• CDC/NHSN. CDC/NHSN surveillance definitions for specific types of infections. Available from: https://www.cdc.gov/nhsn/. pdfs/pscmanual/17pscnosinfdef_current.pdf. Accessed October 27, 2021.
   Google Scholar
• Chen F, Shen C, Pang X, et al. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: a retrospective study. Transpl Infect Dis. 2020;22(1):e13199. doi:10.1111/tid.13199
   Web of Science ®Google Scholar
• Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170–3175. doi:10.1093/jac/dky295
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy492
   PubMed Web of Science ®Google Scholar
• World Health Organization. Model List of Essential Medicines – 22nd List 2021. Geneva: World Health Organization; 2021.
   Google Scholar
• Onorato L, Di Caprio G, Signoriello S, Coppola N. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis. Int J Antimicrob Agents. 2019;54(6):735–740. doi:10.1016/j.ijantimicag.2019.08.025
   PubMed Web of Science ®Google Scholar
• Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis. Antibiotics. 2020;9(7):388. doi:10.3390/antibiotics9070388
   Web of Science ®Google Scholar
• Tamma PD, Fan Y, Bergman Y, et al. Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam. Antimicrob Agents Chemother. 2018;62(4). doi:10.1128/AAC.02213-17
   Web of Science ®Google Scholar
• Algwizani A, Alzunitan M, Alharbi A, et al. Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia. J Infect Public Health. 2018;11(6):793–795. doi:10.1016/j.jiph.2018.04.013
   Web of Science ®Google Scholar
• Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. doi:10.1056/NEJMoa2102953
   PubMed Web of Science ®Google Scholar